Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240847 | 0.91 | OPRD1 (0.37) | OPRD1 | |
| SCHEMBL2624421 | 0.90 | NPY5R (0.33) | OPRD1 | |
| SCHEMBL10249726 | 0.89 | OPRD1 (0.31) | OPRD1 | |
| SCHEMBL4953415 | 0.88 | NR1I2 (0.33) | OPRD1 | |
| SCHEMBL4953421 | 0.88 | NR1I2 (0.33) | OPRD1 | |
| SCHEMBL2619792 | 0.88 | OPRD1 (0.38) | OPRD1OPRM1SIGMAR1OPRL1 | |
| SCHEMBL2619517 | 0.88 | OPRM1 (0.33) | OPRD1OPRM1SIGMAR1OPRL1 | |
| SCHEMBL2105108 | 0.87 | NR1I2 (0.39) | — | |
| SCHEMBL2611948 | 0.87 | NR1I2 (0.39) | — | |
| SCHEMBL2624348 | 0.87 | OPRM1 (0.44) | OPRD1OPRM1SIGMAR1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158675-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-04-17 | — | — | US | disclosed |
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, YBX1, HAX1 | OPRD1 3214/4885OPRM1 2904/4885SIGMAR1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.